# Brookings Proposes Transferring Drug Quotas

A Brookings Institution analysis argues that the Drug Enforcement Administration’s authority to set production quotas for certain medicines may contribute to recurring shortages and recommends transferring that role to the Food and Drug Administration. The proposal does not represent an enacted change or an active solicitation, but it raises a potential shift in federal oversight relevant to pharmaceutical supply planning.

- Pharmaceutical manufacturers and suppliers should distinguish the analysis’s recommendation from current requirements: the signal reports no change to DEA authority or production quotas.
- There is no contract opportunity identified. The proposal could be relevant to future production planning if federal oversight or quota-setting responsibilities change.

**Jurisdictions:** federal
**Industries:** Healthcare
**Topics:** Regulatory Compliance
**Published:** November 20, 2026

### Government Entities
- Drug Enforcement Administration (DEA)
- Food and Drug Administration (FDA)

### Sources
- [
        The agency best known for fighting illegal drugs also decides how much of some legal drugs can be made - Federal News Network](https://federalnewsnetwork.com/podcast/federal-drive-with-terry-gerton-podcast/the-agency-best-known-for-fighting-illegal-drugs-also-decides-how-much-of-some-legal-drugs-can-be-made) - Federal News Network